Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor

Cristina Puy, Erik I. Tucker, Anton Matafonov, Qiufang Cheng, Keith D. Zientek, Dave Gailani, András Gruber, Owen J T McCarty

    Research output: Contribution to journalArticle

    26 Citations (Scopus)

    Abstract

    Activation of coagulation factor XI (FXI) may play a role in hemostasis. The primary substrate of activated FXI (FXIa) is FIX, leading to FX activation (FXa) and thrombin generation. However, recent studies suggest the hemostatic role of FXI may not be restricted to the activation of FIX. We explored whether FXI could interact with and inhibit the activity of tissue factor pathway inhibitor (TFPI). TFPI is an essential reversible inhibitor of activated factor X (FXa) and also inhibits the FVIIa-TF complex. We found that FXIa neutralized both endothelium- and platelet-derived TFPI by cleaving the protein between the Kunitz (K) 1 and K2 domains (Lys86/Thr87) and at the active sites of the K2 (Arg107/Gly108) and K3 (Arg199/Ala200) domains. Addition of FXIa to plasma was able to reverse the ability of TFPI to prolong TF-initiated clotting times in FXI- or FIX-deficient plasma, as well as FXa-initiated clotting times in FX-deficient plasma. Treatment of cultured endothelial cells with FXIa increased the generation of FXa and promoted TF-dependent fibrin formation in recalcified plasma. Together, these results suggest that the hemostatic role of FXIa may be attributed not only to activation of FIX but also to promoting the extrinsic pathway of thrombin generation through inactivation of TFPI.

    Original languageEnglish
    Pages (from-to)1488-1496
    Number of pages9
    JournalBlood
    Volume125
    Issue number9
    DOIs
    Publication statusPublished - 26 Feb 2015

    Fingerprint

    Factor XIa
    Factor XI
    Chemical activation
    Hemostatics
    Thrombin
    Plasmas
    Factor Xa
    Hemostasis
    Fibrin
    Endothelium
    Cultured Cells
    Catalytic Domain
    Endothelial cells
    Blood Platelets
    Endothelial Cells
    Platelets
    lipoprotein-associated coagulation inhibitor
    Proteins

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this

    Puy, C., Tucker, E. I., Matafonov, A., Cheng, Q., Zientek, K. D., Gailani, D., ... McCarty, O. J. T. (2015). Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor. Blood, 125(9), 1488-1496. https://doi.org/10.1182/blood-2014-10-604587

    Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor. / Puy, Cristina; Tucker, Erik I.; Matafonov, Anton; Cheng, Qiufang; Zientek, Keith D.; Gailani, Dave; Gruber, András; McCarty, Owen J T.

    In: Blood, Vol. 125, No. 9, 26.02.2015, p. 1488-1496.

    Research output: Contribution to journalArticle

    Puy, C, Tucker, EI, Matafonov, A, Cheng, Q, Zientek, KD, Gailani, D, Gruber, A & McCarty, OJT 2015, 'Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor', Blood, vol. 125, no. 9, pp. 1488-1496. https://doi.org/10.1182/blood-2014-10-604587
    Puy, Cristina ; Tucker, Erik I. ; Matafonov, Anton ; Cheng, Qiufang ; Zientek, Keith D. ; Gailani, Dave ; Gruber, András ; McCarty, Owen J T. / Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor. In: Blood. 2015 ; Vol. 125, No. 9. pp. 1488-1496.
    @article{7ebeb21188c342a792e5c20621caae46,
    title = "Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor",
    abstract = "Activation of coagulation factor XI (FXI) may play a role in hemostasis. The primary substrate of activated FXI (FXIa) is FIX, leading to FX activation (FXa) and thrombin generation. However, recent studies suggest the hemostatic role of FXI may not be restricted to the activation of FIX. We explored whether FXI could interact with and inhibit the activity of tissue factor pathway inhibitor (TFPI). TFPI is an essential reversible inhibitor of activated factor X (FXa) and also inhibits the FVIIa-TF complex. We found that FXIa neutralized both endothelium- and platelet-derived TFPI by cleaving the protein between the Kunitz (K) 1 and K2 domains (Lys86/Thr87) and at the active sites of the K2 (Arg107/Gly108) and K3 (Arg199/Ala200) domains. Addition of FXIa to plasma was able to reverse the ability of TFPI to prolong TF-initiated clotting times in FXI- or FIX-deficient plasma, as well as FXa-initiated clotting times in FX-deficient plasma. Treatment of cultured endothelial cells with FXIa increased the generation of FXa and promoted TF-dependent fibrin formation in recalcified plasma. Together, these results suggest that the hemostatic role of FXIa may be attributed not only to activation of FIX but also to promoting the extrinsic pathway of thrombin generation through inactivation of TFPI.",
    author = "Cristina Puy and Tucker, {Erik I.} and Anton Matafonov and Qiufang Cheng and Zientek, {Keith D.} and Dave Gailani and Andr{\'a}s Gruber and McCarty, {Owen J T}",
    year = "2015",
    month = "2",
    day = "26",
    doi = "10.1182/blood-2014-10-604587",
    language = "English",
    volume = "125",
    pages = "1488--1496",
    journal = "Blood",
    issn = "0006-4971",
    publisher = "American Society of Hematology",
    number = "9",

    }

    TY - JOUR

    T1 - Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor

    AU - Puy, Cristina

    AU - Tucker, Erik I.

    AU - Matafonov, Anton

    AU - Cheng, Qiufang

    AU - Zientek, Keith D.

    AU - Gailani, Dave

    AU - Gruber, András

    AU - McCarty, Owen J T

    PY - 2015/2/26

    Y1 - 2015/2/26

    N2 - Activation of coagulation factor XI (FXI) may play a role in hemostasis. The primary substrate of activated FXI (FXIa) is FIX, leading to FX activation (FXa) and thrombin generation. However, recent studies suggest the hemostatic role of FXI may not be restricted to the activation of FIX. We explored whether FXI could interact with and inhibit the activity of tissue factor pathway inhibitor (TFPI). TFPI is an essential reversible inhibitor of activated factor X (FXa) and also inhibits the FVIIa-TF complex. We found that FXIa neutralized both endothelium- and platelet-derived TFPI by cleaving the protein between the Kunitz (K) 1 and K2 domains (Lys86/Thr87) and at the active sites of the K2 (Arg107/Gly108) and K3 (Arg199/Ala200) domains. Addition of FXIa to plasma was able to reverse the ability of TFPI to prolong TF-initiated clotting times in FXI- or FIX-deficient plasma, as well as FXa-initiated clotting times in FX-deficient plasma. Treatment of cultured endothelial cells with FXIa increased the generation of FXa and promoted TF-dependent fibrin formation in recalcified plasma. Together, these results suggest that the hemostatic role of FXIa may be attributed not only to activation of FIX but also to promoting the extrinsic pathway of thrombin generation through inactivation of TFPI.

    AB - Activation of coagulation factor XI (FXI) may play a role in hemostasis. The primary substrate of activated FXI (FXIa) is FIX, leading to FX activation (FXa) and thrombin generation. However, recent studies suggest the hemostatic role of FXI may not be restricted to the activation of FIX. We explored whether FXI could interact with and inhibit the activity of tissue factor pathway inhibitor (TFPI). TFPI is an essential reversible inhibitor of activated factor X (FXa) and also inhibits the FVIIa-TF complex. We found that FXIa neutralized both endothelium- and platelet-derived TFPI by cleaving the protein between the Kunitz (K) 1 and K2 domains (Lys86/Thr87) and at the active sites of the K2 (Arg107/Gly108) and K3 (Arg199/Ala200) domains. Addition of FXIa to plasma was able to reverse the ability of TFPI to prolong TF-initiated clotting times in FXI- or FIX-deficient plasma, as well as FXa-initiated clotting times in FX-deficient plasma. Treatment of cultured endothelial cells with FXIa increased the generation of FXa and promoted TF-dependent fibrin formation in recalcified plasma. Together, these results suggest that the hemostatic role of FXIa may be attributed not only to activation of FIX but also to promoting the extrinsic pathway of thrombin generation through inactivation of TFPI.

    UR - http://www.scopus.com/inward/record.url?scp=84937984556&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84937984556&partnerID=8YFLogxK

    U2 - 10.1182/blood-2014-10-604587

    DO - 10.1182/blood-2014-10-604587

    M3 - Article

    C2 - 25587039

    AN - SCOPUS:84937984556

    VL - 125

    SP - 1488

    EP - 1496

    JO - Blood

    JF - Blood

    SN - 0006-4971

    IS - 9

    ER -